We are live on
!
Find out more
RG
Redmile Group Portfolio holdings
AUM
$1.49B
Turnover
10.26%
1-Year Est. Return
208.7%
This Fund
S&P 500
This Quarter
Est. Return
+4.96%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$1.51B
AUM Growth
+$152M
(+11%)
Cap. Flow
+$148M
Cap. Flow
% of AUM
9.78%
Top 10 Holdings %
Top 10 Hldgs %
81.92%
Holding
39
New
5
Increased
6
Reduced
16
Closed
4
Avg Time Held
4.1
years
Top 10 Avg Time Held
1.2
years
Top 20 Avg Time Held
1.5
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Scholar Rock
SRRK
|
+$172M |
| 2 |
Annexon
ANNX
|
+$25.3M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
+$10.1M |
| 4 |
ALX Oncology
ALXO
|
+$8.95M |
| 5 |
Prime Medicine
PRME
|
+$6.05M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RAPT Therapeutics
RAPT
|
+$30M |
| 2 |
Cogent Biosciences
COGT
|
+$27.7M |
| 3 |
Replimune Group
REPL
|
+$10.7M |
| 4 |
IDEAYA Biosciences
IDYA
|
+$7.41M |
| 5 |
Nurix Therapeutics
NRIX
|
+$5.99M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
LivaNova
LIVN
$4.32B
| $6.89M | 0.46% |
108,354
-9,700
| -8% | -$626K |
2021 Q1
20 quarters
|
|
27
Establishment Labs
ESTA
$1.83B
| $5.87M | 0.39% |
103,464
-9,200
| -8% | -$628K |
2024 Q1
8 quarters
|
|
|
28
Prime Medicine
PRME
$655M
| $5.54M | 0.37% |
+1,590,832
| New | +$6.05M |
2026 Q1
0 quarters
|
|
29
Oric Pharmaceuticals
ORIC
$1.32B
| $5.27M | 0.35% |
415,710
-32,400
| -7% | -$368K |
2025 Q4
1 quarter
|
|
30
Eupraxia Pharmaceuticals
EPRX
$447M
| $5.07M | 0.34% |
+700,000
| New | +$5.63M |
2026 Q1
0 quarters
|
|
31
Ardelyx
ARDX
$844M
| $4.39M | 0.29% |
+733,350
| New | +$4.85M |
2026 Q1
0 quarters
|
|
32
Invivyd
IVVD
$197M
| $3.44M | 0.23% |
2,648,659
-32,500
| -1% | -$59.7K |
2021 Q3
18 quarters
|
|
33
Atara Biotherapeutics
ATRA
$96.9M
| $2.09M | 0.14% |
441,701
| – | – |
2014 Q4
45 quarters
|
|
34
AgomAb Therapeutics NV
AGMB
$410M
| $1.64M | 0.11% |
+156,250
| New | +$2.21M |
2026 Q1
0 quarters
|
|
35
Pliant Therapeutics
PLRX
$60.2M
| $973K | 0.06% |
772,126
-844,102
| -52% | -$1.07M |
2020 Q2
23 quarters
|
|
|
36
DELISTED
RAPT Therapeutics
RAPT
| – | – |
-885,927
| Closed | -$30M | – |
|
|
37
Replimune Group
REPL
$1.11B
| – | – |
-1,099,756
| Closed | -$10.7M | – |
|
38
DELISTED
Repare Therapeutics
RPTX
| – | – |
-1,586,174
| Closed | -$4.12M | – |
|
39
Kalaris Therapeutics
KLRS
$52.1M
| – | – |
-82,955
| Closed | -$700K | – |
|
Similar funds
FCM
MM
WA
ACB
LCS
GAM
MFWP
PMG
Redmile Group's Q1 2026 Portfolio in Review
As of Q1 2026, Redmile Group held 39 positions worth $1.51B, up 11% from $1.36B the previous quarter. Its ten largest holdings account for 82% of the portfolio.
Redmile Group deployed $148M of net new capital in Q1 2026, opening 5 new positions and adding to 6 existing holdings. Its largest new stake was BioMarin Pharmaceuticals: 173,859 shares worth $9.82M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was Cogent Biosciences, an estimated $27.7M trimmed.
- Redmile Group's largest Q1 2026 buy was BioMarin Pharmaceuticals: 173,859 shares worth $9.82M.
- Redmile Group added most to Scholar Rock in Q1 2026, an estimated $172M increase.
- Redmile Group's biggest Q1 2026 reduction was Cogent Biosciences, cutting an estimated $27.7M.
- Redmile Group fully exited RAPT Therapeutics in Q1 2026, selling an estimated $30M.
- Redmile Group's ten largest holdings make up 82% of its $1.51B portfolio in Q1 2026.
- Redmile Group opened 5 new positions and closed 4 in Q1 2026.
- Redmile Group's portfolio value rose 11% quarter-over-quarter to $1.51B.
Based on Redmile Group's 13F filing for Q1 2026, filed 15 May 2026.